DEFB105A
Beta-defensin 105
Also known as: D105A_HUMAN, DEFB-5, DEFB105, DEFB105B
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8NG35
- Gene
- DEFB105A
- Ensembl
- ENSG00000186562
- Chromosome
- 8
- Canonical length
- 78 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils. Defensins are short, processed peptide molecules that are classified by structure into three groups: alpha-defensins, beta-defensins and theta-defensins. All beta-defensin genes are densely clustered in four to five syntenic chromosomal regions. Chromosome 8p23 contains at least two copies of the duplicated beta-defensin cluster. This duplication results in two identical copies of defensin, beta 105, DEFB105A and DEFB105B, in tail-to-tail orientation. This gene, DEFB105A, represents the more centromeric copy. [provided by RefSeq, Oct 2014]
Canonical amino-acid sequenceUniProt
78 residues, UniProt reviewed canonical sequence.
>Q8NG35|DEFB105A
1 MALIRKTFYF LFAMFFILVQ LPSGCQAGLD FSQPFPSGEF AVCESCKLGR GKCRKECLEN
61 EKPDGNCRLN FLCCRQRILocalizationUniProt · AlphaFold · HPA
Whether an antibody against DEFB105A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.49
- Highest tissue expression
- 1,166 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 1,166 nTPM
- bone marrow: 0.5 nTPM
- skin: 0.4 nTPM
- appendix: 0.3 nTPM
- lymph node: 0.3 nTPM
- retina: 0.3 nTPM
Single-cell type
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
- astrocytes: 0 nCPM
Immune cell
- basophil: 2.9 nTPM
- neutrophil: 1.4 nTPM
- NK-cell: 0.9 nTPM
- naive B-cell: 0.7 nTPM
- memory B-cell: 0.5 nTPM
- plasmacytoid DC: 0.5 nTPM
Brain region
- cerebellum: 6.5 nTPM
- white matter: 6 nTPM
- cerebral cortex: 5.5 nTPM
- amygdala: 5.2 nTPM
- medulla oblongata: 5.2 nTPM
- thalamus: 5.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.76
- gnomAD pLI
- 0.38
- gnomAD missense Z
- -0.36
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 0% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DEFB105A as an antibody target. Whether an autoantibody or antibody against DEFB105A could matter depends on whether native DEFB105A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DEFB105A is annotated as secreted, so native DEFB105A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label DEFB105A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...